A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
Status:
Completed
Trial end date:
2017-05-11
Target enrollment:
Participant gender:
Summary
A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of
ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic
heart failure.